Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021

Rhea-AI Summary

On May 18, 2021, Calliditas Therapeutics will release its Q1 2021 financial report and hold a conference call at 2.30 pm CET to discuss the results. The call will be led by CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, conducted in English, and will be available via webcast. Calliditas focuses on innovative treatments for orphan diseases, particularly renal and hepatic conditions. Its lead product candidate, Nefecon, targets the autoimmune renal disease IgA nephropathy. The company trades on Nasdaq with the ticker CALT.

STOCKHOLM, May 14, 2021 /PRNewswire/ -- On May 18^th, 2021, Calliditas Therapeutics AB (publ) ("Calliditas") will publish its financial report for the first quarter of 2021, and at 2.30 pm CET will host a conference call to present and discuss the results.

The event will be hosted by the company's CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, and will be held in English. The presentation will be webcast live and will also be made available online on the Calliditas website after the call.

Webcast link: https://tv.streamfabriken.com/calliditas-therapeutics-q1-2021

Teleconference: SE: +46850558366 UK: + 443333009271  US: + 18335268381

For further information, please contact:

Marie Galay, IR Manager, Calliditas

Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com

The information was sent for publication, through the agency of the contact person set out above, on May 14, 2021 at 2:00 p.m. CET.

About Calliditas

Calliditas Therapeutics is a biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas successfully reported top line data of its global Phase 3 study in IgAN in November of 2020 and, if approved, aims to commercialize Nefecon in the United States on its own and partner elsewhere. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit www.calliditas.com for further information.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/calliditas-therapeutics/r/calliditas-therapeutics-to-host-conference-call-to-provide-business-update-for-the-first-quarter-of-,c3346790

The following files are available for download:

https://mb.cision.com/Main/16574/3346790/1417298.pdf

Q1 Inv Call ENG

View original content:http://www.prnewswire.com/news-releases/calliditas-therapeutics-to-host-conference-call-to-provide-business-update-for-the-first-quarter-of-2021-301291671.html

SOURCE Calliditas Therapeutics

FAQ

When will Calliditas publish its Q1 2021 financial results?

Calliditas will publish its Q1 2021 financial report on May 18, 2021.

What time is the Calliditas conference call scheduled for on May 18, 2021?

The conference call is scheduled for 2.30 pm CET on May 18, 2021.

Who will host the Calliditas conference call for Q1 2021 results?

The conference call will be hosted by CEO Renée Aguiar-Lucander and CFO Fredrik Johansson.

What is Nefecon, the lead product candidate of Calliditas?

Nefecon is a proprietary oral formulation of budesonide, aimed at treating the autoimmune renal disease IgA nephropathy.

What is the stock ticker for Calliditas?

Calliditas trades on Nasdaq under the ticker symbol CALT.